BioSig Technologies Adds Role of Manufacturing Project Leader as Company Continues to Advance Towards Commercialization
24 oct. 2017 08h00 HE
|
BioSig Technologies, Inc.
Minneapolis, MN, Oct. 24, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need...
BioSig Technologies Advances Towards Commercialization into the Global Electrophysiology Market Estimated to Reach $8.2 Billion by 2022
19 oct. 2017 08h00 HE
|
BioSig Technologies, Inc.
Minneapolis, MN, Oct. 19, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need within...
BioSig Technologies to Present at the Dawson James Small Cap Growth Conference
13 oct. 2017 08h00 HE
|
BioSig Technologies, Inc.
Minneapolis, MN, Oct. 13, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need...
BioSig Technologies Welcomes Joseph W. Rafferty as Chief Commercialization Officer
11 oct. 2017 08h00 HE
|
BioSig Technologies, Inc.
Minneapolis, MN, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need...
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
16 août 2017 08h30 HE
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 WESTMINSTER,...
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
09 août 2017 16h30 HE
|
ARCA Biopharma, Inc.
ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA WESTMINSTER, Colo., Aug. 09, 2017 (GLOBE...
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update
03 août 2017 16h15 HE
|
ARCA Biopharma, Inc.
WESTMINSTER, Colo., Aug. 03, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017
20 juin 2017 08h30 HE
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation Gencaro Development Program Previously Granted Fast Track Designation by U.S. FDA ...
BioSig Technologies Welcomes Natasha Russkina as Managing Director, Europe
31 mai 2017 03h00 HE
|
BioSig Technologies, Inc.
MINNEAPOLIS, May 31, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for...
ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update
15 mai 2017 08h30 HE
|
ARCA Biopharma, Inc.
WESTMINSTER, Colo., May 15, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...